Target intensity of anticoagulation with warfarin in japanese patients with valvular atrial fibrillation: Subanalysis of the J-RHYTHM registry

Circulation Journal

Volumn 79, Issue 2, 2015, Pages 325-330

  Kodani, Eitaro ^a   Atarashi, Hirotsugu ^a   Inoue, Hiroshi ^b   Okumura, Ken ^c   Yamashita, Takeshi ^d  

^a NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

Anticoagulation; Atrial fibrillation; International normalized ratio; Valvular disease; Warfarin

Indexed keywords

PROTHROMBIN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN INFARCTION; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART VALVE REPLACEMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE STENOSIS; THROMBOEMBOLISM; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; JAPAN; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; THROMBOEMBOLISM; WARFARIN;

EID: 84928237555     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-1057     Document Type: Article

References (22)

1. Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: Current evidence and future trends. Lancet 2009; 374: 565-576.
2. Stassano P, Di Tommaso L, Monaco M, Iorio F, Pepino P, Spampinato N, et al. Aortic valve replacement: A prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years. J Am Coll Cardiol 2009; 54: 1862-1868.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
4. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484.
5. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635-641.
6. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354, doi: 10.1161/CIRCULATIONAHA.106.177292.
7. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version. Circ J 2010; 74: 2479-2500.
8. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation: Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
9. Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation: The J-RHYTHM Registry study design. J Cardiol 2011; 57: 95-99.
10. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: A report from the J-RHYTHM Registry. Circ J 2011; 75: 1328-1333.
11. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
12. Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: Results of the J-RHYTHM Registry. Circ J 2013; 77: 2264-2270.
13. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-2496.
14. Torn M, Cannegieter SC, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: A prospective study of 4202 patients. Arch Intern Med 2009; 169: 1203-1209.
15. Akao M, Chun YH, Esato M, Abe M, Tsuji H, Wada H, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J 2014; 78: 2166-2172.
16. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-315.
17. Suzuki S, Yamashita T, Kato T, Fujino T, Sagara K, Sawada H, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J 2007; 71: 761-765.
18. Matsuyama K, Matsumoto M, Sugita T, Nishizawa J, Yoshida K, Tokuda Y, et al. Anticoagulant therapy in Japanese patients with mechanical mitral valves. Circ J 2002; 66: 668-670.
19. Mori T, Asano M, Ohtake H, Bitoh A, Sekiguchi S, Matsuo Y, et al. Anticoagulant therapy after prosthetic valve replacement: Optimal PT-INR in Japanese patients. Ann Thorac Cardiovasc Surg 2002; 8: 83-87.
20. Johnson JA. Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics. Circulation 2008; 118: 1383-1393.
21. Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee JD, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006; 70: 651-656.
22. J-RHYTHM Registry Investigators. Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan: Subanalysis of the J-RHYTHM Registry. Circ J 2011; 75: 2357-2362.